Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))

MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC

NEW YORK, April 16, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  

MindMed is developing 18-MC as a potential treatment for ...

Continue Reading →

Universal Ibogaine Fighting Opioid Dependency with Plant-Based Medicine

Fighting Opioid Dependency with Plant-Based Medicine

This Universal Ibogaine profile is part of a paid investor education campaign.*


Universal Ibogaine is a Canadian company working to develop compounds to combat the opioid epidemic through plant-based medicine. The company aims to operate and franchise clinics around the world, offering ibogaine as a treatment for opioid-based withdrawals.

Opioids can be found in a number of licit and ...

Continue Reading →

How psychedelic medicine is being used in the fight to end opioid addiction

CEO and co-founder of ATAI Life Sciences, Florian Brand explains why one psychedelic medicine might provide the key to fighting opioid addiction. 

No one wakes up one day and decides to become opioid dependent. You might have been warned against the risks – aware that there’s a chance of developing a tolerance or dependence on the drugs. At the start they block the pain and release that feel-good ...

Continue Reading →
Page 1 of 35 12345...»